Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}

Market Intelligence Analysis

AI-Powered
Why This Matters

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.

Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Continue Reading
Full article on CNBC
Read Full Article
Original article published by CNBC on March 25, 2026.
Analysis and insights provided by AnalystMarkets AI.